Journal article

Optimization of Adiponectin-Derived Peptides for Inhibition of Cancer Cell Growth and Signaling

Laszlo Otvos, Ilona Kovalszky, Julia Olah, Roberta Coroniti, Daniel Knappe, Friederike I Nollmann, Ralf Hoffmann, John D Wade, Sandor Lovas, Eva Surmacz

BIOPOLYMERS | WILEY | Published : 2015


Adiponectin, an adipose tissue-excreted adipokine plays protective roles in metabolic and cardiovascular diseases and exerts anti-cancer activities, partially by interfering with leptin-induced signaling. Previously we identified the active site in the adiponectin protein, and generated both a nanomolar monomeric agonist of the adiponectin receptor (10-mer ADP355) and an antagonist (8-mer ADP400) to modulate various adiponectin receptor-mediated cellular functions. As physiologically circulating adiponectin forms multimeric complexes, we also generated an agonist dimer with improved biodistribution and in vitro efficacy. In the current report, we attempted to optimize the monomeric agonist s..

View full abstract


Funding Acknowledgements

Contract grant sponsor: National Institutes of HealthContract grant sponsor: Subcontract (to L.O.)Contract grant number: AR064925 (to John Varga, Northwestern University)Contract grant sponsor: Novo Nordisk Diabetes Innovation Award (to E.S.); NHMRC (Australia) Principal Research Fellow (to J.D.W.); Victorian Government Operational Infrastructure Support Program (to Research at the Florey Institute of Neuroscience and Mental Health).